AKT1 and Hyperglycemia: Inter‐rater reliability (calculated as the percent‐time that two reviewers agreed on a metric) was 96% for presence of hyperglycemia‐related treatment interruption and 100% for presence of PI3K/ AKT inhibitor exposure, based on 80 chart reviews.